Thermo Fisher Scientific Acquires Olink

Image Credit: Adobe Stock Images/stockphoto-Sophia

Thermo Fisher Scientific and Olink announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash. The transaction, which is expected to be finished by mid-2024, is valued at an estimated 3.1 billion which includes net cash of approximately $143 million.

“The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine,” said Marc N. Casper, chairman, president, CEO, Thermo Fisher. “Olink’s proven and transformative innovation is highly complementary to our leading mass spectrometry and life sciences platforms. Our company is uniquely positioned to bring this technology to customers enabling them to meaningfully accelerate discovery and scientific breakthroughs. We look forward to welcoming Olink’s colleagues to Thermo Fisher.”

Reference: Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics. Thermo Fisher Scientific. October 17, 2023. Accessed October 19, 2023. https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2023/Thermo-Fisher-Scientific-to-Acquire-Olink-a-Leader-in-Next-Generation-Proteomics/default.aspx